Brought to you by 
Symphony finances development of three Lexicon candidates; Lexicon later reacquires development rights
24 Jun 2020
Executive Summary
Lexicon Pharmaceuticals and private equity company Symphony Capital have formed Symphony Icon, a financing vehicle, with $45mm to fund development of Lexicon's three most advanced candidates over a four-year period.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Special-Purpose Financing Vehicle
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Symphony finances development of three Lexicon candidates; Lexicon later reacquires development rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice